3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
4
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Carcinoma, Renal Cell
3
Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Interventions
nilotinib
50
Imatinib Mesylate
48
Dasatinib
25
bosutinib
18
asciminib
17
ponatinib
10
Homoharringtonine
5
Cytarabine
4
olverembatinib
3
Interferon-alpha
3
Decitabine
3
tozasertib
2
peginterferon alfa-2a
2
flumatinib
2
fludarabine phosphate
2
ON 01910
2
Mycophenolic Acid
2
Melphalan
2
Interferon alpha-2
2
Filgrastim
2
Cyclophosphamide
2
Bone Marrow Transplantation
2
BID protein, human
2
Azacitidine
2
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide
2
vosaroxin
1
troxacitabine
1
triciribine
1
terameprocol
1
sonidegib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
×
Tyrosine Kinase Inhibitors
×
Clear all
NCT05476562
2022-11-08
Study Conducted Among Patients With CML
Novartis
Completed
3,234 enrolled